238 related articles for article (PubMed ID: 19199782)
21. Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands.
Zheng Y; Obeng S; Wang H; Jali AM; Peddibhotla B; Williams DA; Zou C; Stevens DL; Dewey WL; Akbarali HI; Selley DE; Zhang Y
J Med Chem; 2019 Jan; 62(2):561-574. PubMed ID: 30608693
[TBL] [Abstract][Full Text] [Related]
22. Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
Neumeyer JL; Zhang A; Xiong W; Gu XH; Hilbert JE; Knapp BI; Negus SS; Mello NK; Bidlack JM
J Med Chem; 2003 Nov; 46(24):5162-70. PubMed ID: 14613319
[TBL] [Abstract][Full Text] [Related]
23. Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.
Hiebel AC; Lee YS; Bilsky E; Giuvelis D; Deschamps JR; Parrish DA; Aceto MD; May EL; Harris LS; Coop A; Dersch CM; Partilla JS; Rothman RB; Cheng K; Jacobson AE; Rice KC
J Med Chem; 2007 Aug; 50(16):3765-76. PubMed ID: 17625813
[TBL] [Abstract][Full Text] [Related]
24. Mixed kappa/mu opioid receptor agonists: the 6 beta-naltrexamines.
Cami-Kobeci G; Neal AP; Bradbury FA; Purington LC; Aceto MD; Harris LS; Lewis JW; Traynor JR; Husbands SM
J Med Chem; 2009 Mar; 52(6):1546-52. PubMed ID: 19253970
[TBL] [Abstract][Full Text] [Related]
25. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
[TBL] [Abstract][Full Text] [Related]
26. Aminothiazolomorphinans with mixed κ and μ opioid activity.
Zhang T; Yan Z; Sromek A; Knapp BI; Scrimale T; Bidlack JM; Neumeyer JL
J Med Chem; 2011 Mar; 54(6):1903-13. PubMed ID: 21351746
[TBL] [Abstract][Full Text] [Related]
27. SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.
Xu H; Lu YF; Rice KC; Ananthan S; Rothman RB
Brain Res Bull; 2001 Jul; 55(4):507-11. PubMed ID: 11543951
[TBL] [Abstract][Full Text] [Related]
28. Structure selectivity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives toward the development of the mu opioid receptor antagonists.
Yuan Y; Elbegdorj O; Chen J; Akubathini SK; Beletskaya IO; Selley DE; Zhang Y
Bioorg Med Chem Lett; 2011 Sep; 21(18):5625-9. PubMed ID: 21788135
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodime.
Spetea M; Schüllner F; Moisa RC; Berzetei-Gurske IP; Schraml B; Dörfler C; Aceto MD; Harris LS; Coop A; Schmidhammer H
J Med Chem; 2004 Jun; 47(12):3242-7. PubMed ID: 15163203
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and characterization of 6beta-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes.
Pelotte AL; Smith RM; Ayestas M; Dersch CM; Bilsky EJ; Rothman RB; Deveau AM
Bioorg Med Chem Lett; 2009 May; 19(10):2811-4. PubMed ID: 19364645
[TBL] [Abstract][Full Text] [Related]
31. Effect of N-alkyl and N-alkenyl substituents in noroxymorphindole, 17-substituted-6,7-dehydro-4,5alpha-epoxy-3,14-dihydroxy-6,7:2',3'-indolomorphinans, on opioid receptor affinity, selectivity, and efficacy.
McLamore S; Ullrich T; Rothman RB; Xu H; Dersch C; Coop A; Davis P; Porreca F; Jacobson AE; Rice KC
J Med Chem; 2001 Apr; 44(9):1471-4. PubMed ID: 11311071
[TBL] [Abstract][Full Text] [Related]
32. Cinnamoyl derivatives of 7alpha-aminomethyl-6,14-endo-ethanotetrahydrothebaine and 7alpha-aminomethyl-6,14-endo-ethanotetrahydrooripavine and related opioid ligands.
Rennison D; Neal AP; Cami-Kobeci G; Aceto MD; Martinez-Bermejo F; Lewis JW; Husbands SM
J Med Chem; 2007 Oct; 50(21):5176-82. PubMed ID: 17887741
[TBL] [Abstract][Full Text] [Related]
33. Synthesis, Pharmacology, and Molecular Docking Studies on 6-Desoxo-N-methylmorphinans as Potent μ-Opioid Receptor Agonists.
Dumitrascuta M; Ben Haddou T; Guerrieri E; Noha SM; Schläfer L; Schmidhammer H; Spetea M
J Med Chem; 2017 Nov; 60(22):9407-9412. PubMed ID: 29053268
[TBL] [Abstract][Full Text] [Related]
34. Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities.
Healy JR; Bezawada P; Shim J; Jones JW; Kane MA; MacKerell AD; Coop A; Matsumoto RR
ACS Chem Neurosci; 2013 Sep; 4(9):1256-66. PubMed ID: 23713721
[TBL] [Abstract][Full Text] [Related]
35. The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone.
Beattie DT; Cheruvu M; Mai N; O'Keefe M; Johnson-Rabidoux S; Peterson C; Kaufman E; Vickery R
Naunyn Schmiedebergs Arch Pharmacol; 2007 May; 375(3):205-20. PubMed ID: 17340127
[TBL] [Abstract][Full Text] [Related]
36. 14-Alkoxy- and 14-acyloxypyridomorphinans: μ agonist/δ antagonist opioid analgesics with diminished tolerance and dependence side effects.
Ananthan S; Saini SK; Dersch CM; Xu H; McGlinchey N; Giuvelis D; Bilsky EJ; Rothman RB
J Med Chem; 2012 Oct; 55(19):8350-63. PubMed ID: 23016952
[TBL] [Abstract][Full Text] [Related]
37. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
38. 6β-N-heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral mu opioid receptor selective antagonists.
Yuan Y; Stevens DL; Braithwaite A; Scoggins KL; Bilsky EJ; Akbarali HI; Dewey WL; Zhang Y
Bioorg Med Chem Lett; 2012 Jul; 22(14):4731-4. PubMed ID: 22683223
[TBL] [Abstract][Full Text] [Related]
39. 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion.
Zhang Y; Williams DA; Zaidi SA; Yuan Y; Braithwaite A; Bilsky EJ; Dewey WL; Akbarali HI; Streicher JM; Selley DE
ACS Chem Neurosci; 2016 Mar; 7(3):297-304. PubMed ID: 26716358
[TBL] [Abstract][Full Text] [Related]
40. Affinity, potency, efficacy, selectivity, and molecular modeling of substituted fentanyls at opioid receptors.
Eshleman AJ; Nagarajan S; Wolfrum KM; Reed JF; Nilsen A; Torralva R; Janowsky A
Biochem Pharmacol; 2020 Dec; 182():114293. PubMed ID: 33091380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]